Pamidronate Disodium Dawa (Pamidronate Disodium)

Pamidronate disodium is used primarily for conditions that involve abnormal bone turnover and calcium dysregulation.

• Hypercalcemia of malignancy: reduces the elevated serum calcium levels.
• Osteolytic bone metastases: helps to decrease skeletal related events.
• Paget’s disease of bone: slows the abnormal bone remodeling.
• Primary hyperparathyroidism (pre‑surgical pre‑treatment when needed): assists in temporary calcium control.
• Bone pain associated with metastatic cancer or multiple myeloma – provides analgesic adjunct benefit.

• Pamidronate disodium binds to hydroxy‑apatite crystals on bone surfaces, especially at sites of active remodeling. When osteoclasts attach to the drug‑coated bone, intracellular uptake occurs, leading to inhibition of farnesyl pyrophosphate synthase within the the mevalonate pathway. This blocks prenylation of small GTP‑binding proteins, impairing osteoclast maturation, attachment and resorption activity, thereby reducing bone turnover and calcium release.

Adverse reactions to pamidronate are generally related to infusion and bone‑metabolism effects.

Common Side Effects

• Acute infusion‑related flushing or warmth.
• Mild fever or chills.
• Transient nausea or vomiting.
• Musculoskeletal pain, especially in the hips, shoulders or jaw.
• Elevated serum creatinine or transient renal function changes.

Serious or Rare Side Effects

• Acute renal failure, particularly with rapid or high‑dose infusions.
• Severe hypocalcemia leading to tetany or cardiac arrhythmia.
• Osteonecrosis of the jaw (ONJ), especially after dental procedures.
• Atypical femoral fractures.
• Anaphylactic or severe hypersensitivity reactions.

When using pamidronate, clinicians should assess renal function, electrolyte status and dental health before initiation.

• Renal monitoring: check serum creatinine before each infusion and adjust dose if impairment is present.
• Calcium & vitamin D status: ensure adequate supplementation to reduce hypocalcemia risk.
• Dental evaluation: perform a thorough oral exam and postpone elective invasive dental work during therapy.
• Concomitant nephrotoxic drugs: avoid or use with caution when combined with NSAIDs, aminoglycosides or contrast agents.
• Pregnancy & lactation: contraindicated unless clearly needed; discuss risks with the prescriber.
• Store at below 25°C: keep in the original container, protect from moisture and light.

Pamidcinate may interact with several drug classes that affect renal function or calcium balance.

Major Interactions (Avoid)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) combined with high‑dose pamidronate – increased risk of renal toxicity.
• Aminoglycoside antibiotics – additive nephrotoxic potential.
• Loop diuretics (e.g., furosemide) when used without calcium supplementation – may precipitate severe hypocalcemia.

Moderate Interactions (Monitor Closely)

• Calcium‑containing antacids or supplements taken immediately before infusion – may reduce drug binding to bone.
• Vitamin D analogues (calcitriol) – require monitoring of serum calcium and phosphate.
• Other bisphosphonates or bone‑active agents – cumulative effect on bone turnover and renal function.